-
Media Release
Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan
-
Media Release
Novartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centers
-
Media Release
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer